ArticleAsian Pacific journal of cancer prevention : APJCP2024
Identification of Bioactive and Anticancer Properties of Bidens Pilosa in-vitro Evidence.
Article in Asian Pacific journal of cancer prevention : APJCP, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Exploring the phytochemical profile, antioxidant and anti-inflammatory potential ofFrontiers in pharmacology · 2025Pooled it
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesBidens pilosa and Trianthema portulacastrum are noteworthy weeds with a series of bioactive flavonoid constituents, hence, they can be utilized as potential health supplements and readily available sources of natural antioxidants, as well as effective constituents in medicinal applications. The current study aims to assess the anti-proliferative activity of B. pilosa and T. portulacastrum extracts using the HepG2 cell line. Methods The prepared extracts were evaluated for their cytotoxic influence and their potential CC50 in HepG2 cell lines and normal hepatocytes using the MTT assay. Using quantitative real-time polymerase chain reaction (qRT-PCR), the relative gene expression of Raf-1, MEK-1, LC3B, and Atg12 was quantified in treated cells to detect the expression levels of cell proliferation factors and autophagy-related genes. The quantification analysis of the released interleukin-1beta (IL-1β) and interleukin-1alpha (IL-1α) was also done using an ELISA assay.
resultsThe activities of B. pilosa extract showed an anti-proliferative influence on HepG2 cell lines upon treatment as compared to normal cells. It was assessed for cytotoxicity using molecular studies against both Raf-1 and MEK-1 as proposed anticancer mechanisms and showed promising inhibitory activity against Raf-1 and MEK-1 gene expression. Likewise, the reduction of autophagy-related genes, Atg12 and LC3B, in HepG2 cells pre-treated with B. pilosa extract, further confirmed its influence in the induction of programmed cell death (PCD). The ELISA assay revealed a substantial elevation of the pro-inflammatory cytokines IL-1α and IL-1β upon treatment.
conclusionThis study found that B. pilosa extract, without any detectable cytotoxic effects, had potential inhibitory activities against both Raf-1 and MEK-1 gene expression, and a significant reduction in autophagic machinery upon treatment.<br /> <br />.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.